Skip to content Skip to navigation


AMP RA/Lupus Network

The Accelerating Medicines Partnership (AMP) was launched in February 2014 as a public-private partnership between the National Institutes of Health (NIH), the U.S. Food and Drug Administration (FDA), 10 biopharmaceutical companies, and multiple non-profit organizations. AMP is designed to accelerate discoveries and to improve patient care as rapidly as possible. The AMP Rheumatoid Arthritis (RA)/Lupus Network component of the partnership aims to develop new models for identifying and validating promising biological targets for new diagnostics and treatment of RA, lupus, and related autoimmune diseases by defining shared and disease-specific biological pathways. 

Upcoming Meetings

Currently, no future events are scheduled.

View Past Events

AMP Document System

Absolutely NO Patient Health Information (PHI) may be uploaded and stored in the AMP Document System.

Access AMP Document System

Submit Request to Gain Access to AMP Data Systems